Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, Dezentje VO, Jager A, Hokken JWE, Putter H, van der Velden AWG, Hendriks MP, Bakker SD, van Riet YEA, Tjan-Heijnen VCG, Portielje JEA, Kroep JR, Nortier JWR, van de Velde CJH, Linn SC. Vliek SB, et al. Among authors: van rossum agj. J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442755 Clinical Trial.
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, Opdam M, van Werkhoven E, Hahn K, Nederlof I, Lips EH, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker SD, Rutgers EJ, Horlings HM, Wesseling J, Voest EE, Wessels LFA, Kok M, Oosterkamp HM, van Oudenaarden A, Linn SC, van Rheenen J. Kester L, et al. Among authors: van rossum agj. Clin Cancer Res. 2022 Mar 1;28(5):960-971. doi: 10.1158/1078-0432.CCR-21-1442. Clin Cancer Res. 2022. PMID: 34965952 Free PMC article.
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group. van Rossum AGJ, et al. Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013. Eur J Cancer. 2018. PMID: 30125761 Free article. Clinical Trial.
FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W. Schrijver W, et al. Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12. Mol Oncol. 2018. PMID: 29972720 Free PMC article. Clinical Trial.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC. Baird RD, et al. Among authors: van rossum agj. Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439579 Clinical Trial.
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC. van Rossum AGJ, et al. Oncotarget. 2017 Nov 27;8(69):113531-113542. doi: 10.18632/oncotarget.22697. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371927 Free PMC article.
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
van Rossum AGJ, Mandjes IAM, van Werkhoven E, van Tinteren H, van Leeuwen-Stok AE, Nederlof P, Portielje JEA, van Alphen RJ, Platte E, van den Broek D, Huitema A, Kok M, Linn SC, Oosterkamp HM. van Rossum AGJ, et al. Breast Care (Basel). 2021 Dec;16(6):598-606. doi: 10.1159/000512200. Epub 2021 Jan 22. Breast Care (Basel). 2021. PMID: 35087363 Free PMC article.
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M. de Boo L, et al. Eur J Cancer. 2020 Mar;127:240-250. doi: 10.1016/j.ejca.2019.12.003. Epub 2020 Jan 16. Eur J Cancer. 2020. PMID: 31956037 Clinical Trial.
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.
Joosten SEP, Wellenstein M, Koornstra R, van Rossum A, Sanders J, van der Noort V, Ferrandez MC, Harkes R, Mandjes IAM, Rosing H, Huitema A, Beijnen JH, Wesseling J, van Diest PJ, Horlings HM, Linn SC, Zwart W. Joosten SEP, et al. NPJ Breast Cancer. 2021 Oct 20;7(1):138. doi: 10.1038/s41523-021-00344-3. NPJ Breast Cancer. 2021. PMID: 34671036 Free PMC article.
Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W. Severson TM, et al. Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983. Oncotarget. 2016. PMID: 27129152 Free PMC article. Clinical Trial.
14 results